Product information and disease description Place of product in therapy Approaches to treatment Current treatment options and standard of care

Beta-adrenergic antagonists

5 evidence topics · 4 sources

AAO Preferred Practice Pattern: topical beta-blockers

“Topical beta adrenergic antagonists are commonly prescribed to treat glaucoma and have demonstrated good efficacy and tolerability.” (opens the source at this quote in a new tab)
“Topical beta-blockers may be dosed once or twice daily.” (opens the source at this quote in a new tab)
“Cardioselective beta-blockers (e.g., betaxolol) target beta-1 receptors and minimize, but do not completely eliminate, the risk of pulmonary adverse effects in patients with obstructive airway disease.” (opens the source at this quote in a new tab)

AAO Preferred Practice Pattern: beta-blocker class profile (carteolol, levobunolol, timolol, betaxolol)

Field	Quoted record
Mechanism of action	“Decrease aqueous production”
IOP reduction	“20%–25%”
Potential contraindications	“Chronic obstructive pulmonary disease”; “Asthma”; “CHF”; “Bradycardia”; “Hypotension”

European Glaucoma Society guidelines: relative efficacy and combination use

“The greatest reduction of IOP is obtained with PGAs, followed by non-selective β-blockers, Rh-kinase inhibitors, alpha-adrenergic agonists, selective β-blockers and topical carbonic anhydrase inhibitors.” (opens the source at this quote in a new tab)
“The most frequently used combination is a PGA with a β-blocker.” (opens the source at this quote in a new tab)

NICE NG81: beta-blocker as second choice when prostaglandin analogs are not tolerated

“Offer another pharmacological treatment to people with an IOP of 24 mmHg or more who cannot tolerate their current treatment. The first choice should be an alternative generic PGA, and if this is not tolerated, offer a beta‑blocker.” (opens the source at this quote in a new tab)

Timolol as the active comparator in sustained-release registrational trials

“Both trials are designed to demonstrate noninferiority of the BIM-IOL System to a standard of care commercial IOL plus twice-daily administration of timolol eye drops.” (opens the source at this quote in a new tab)